Clinical Trial Update: Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL) [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating two dose levels of Targretin capsules in participants with refractory cutaneous T-cell lymphoma has completed with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• Targretin (bexarotene)

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Refractory Cutaneous T-cell Lymphoma | Phase 4 | Status: COMPLETED | Results posted: 2019-11-12